{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:40:36Z","timestamp":1792554036683,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Glaucoma is a disease characterized by progressive damage of the optic nerve. Several therapeutic options are available to lower intraocular pressure (IOP). In primary open-angle glaucoma (POAG) patients with inadequate IOP control (or controlled with multiple medical therapies or for whom medical therapy is contraindicated), the implantation of micro-invasive glaucoma surgery devices (MIGS) and concomitant cataract surgery has proved to be more effective in reducing intraocular pressure (IOP), as compared to cataract surgery alone. The objective of this study was to assess the cost-effectiveness of iStent\n                      <jats:italic>inject<\/jats:italic>\n                      \u00ae device with concurrent cataract surgery vs. cataract surgery alone, in patients with mild-to-moderate POAG, adopting the Italian National Health Service (NHS) perspective.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Simulation of outcomes and costs was undertaken using a Markov model with 4 health states and one-month\u2009cycles, that is used to simulate the prognosis of these patients. Efficacy data were obtained from the randomized clinical trial (RCT). A lifetime horizon was adopted in the analysis. A discount rate of 3.5% was applied to both costs and effects. The Italian National Healthcare Service (NHS) perspective was considered, therefore only healthcare direct costs (acquisition of main interventions and subsequent procedures; medications; monitoring and follow-up; adverse events). Model robustness was tested through sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Results of the base-case analysis showed that the total lifetime costs were higher in the iStent inject\u00ae\u2009+\u2009concurrent cataract surgery, compared with the cataract surgery alone group (\u20ac8368.51 vs. \u20ac7134.71 respectively). iStent inject\u00ae\u2009+\u2009concurrent cataract surgery was cost-effective vs. cataract surgery alone, with an incremental cost-effectiveness ratio of \u20ac13,037.01 per quality-adjusted life year (QALY) gained. Both one-way deterministic and probabilistic sensitivity analyses confirmed robustness of base-case results. The cost-effectiveness accessibility curve (CEAC) showed that iStent inject\u00ae\u2009+\u2009cataract surgery would have a 98% probability of being cost-effective, compared to cataract surgery alone, when the willingness to pay (WTP) is equal to \u20ac50,000 per QALY gained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of the cost-utility analysis confirm that iStent inject\u00ae\u2009+\u2009cataract surgery is a cost-effective option for the treatment of patients affected by mild-to-moderate POAG, compared with cataract surgery alone, when evaluated from the Italian NHS perspective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12913-021-06862-x","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T19:04:13Z","timestamp":1629140653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cost-utility analysis of trabecular micro-bypass stents (TBS) in patients with mild-to-moderate open-angle Glaucoma in Italy"],"prefix":"10.1186","volume":"21","author":[{"given":"Antonio Maria","family":"Fea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Buseghin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4445-611X","authenticated-orcid":false,"given":"Gianluca","family":"Furneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Costagliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"6862_CR1","unstructured":"International Agency for the Prevention of Blindness (IABP). Glaucoma. Available: http:\/\/www.iapb.org\/knowledge\/what-is-avoidable-blindness\/glaucoma\/. Accessed 1 July 2021."},{"issue":"18","key":"6862_CR2","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901\u201311. https:\/\/doi.org\/10.1001\/jama.2014.3192.","journal-title":"JAMA"},{"issue":"1","key":"6862_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jcjo.2016.07.013","volume":"52","author":"R Conlon","year":"2017","unstructured":"Conlon R, Saheb H, Ahmed IIK. Glaucoma treatment trends: a review. Can J Ophthalmol. 2017;52(1):114\u201324. https:\/\/doi.org\/10.1016\/j.jcjo.2016.07.013.","journal-title":"Can J Ophthalmol"},{"key":"6862_CR4","unstructured":"(SOI) SOI. Glaucoma - L\u2019importanza di una diagnosi precoce. Available: https:\/\/www.sedesoi.com\/vademecum6.php. Accessed 1 July 2021."},{"key":"6862_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1155\/2015\/795357","volume":"2015","author":"AM Fea","year":"2015","unstructured":"Fea AM, Consolandi G, Zola M, Pignata G, Cannizzo P, Lavia C, et al. Micro-bypass implantation for primary open-angle Glaucoma combined with phacoemulsification : 4-year follow-up. J Opthalmol. 2015;2015:10\u20133. https:\/\/doi.org\/10.1155\/2015\/795357 Hindawi Publishing Corporation.","journal-title":"J Opthalmol"},{"issue":"2","key":"6862_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1874364100903020038","volume":"3","author":"AL Coleman","year":"2009","unstructured":"Coleman AL, Kodjebacheva G. Risk factors for Glaucoma needing more attention. Open Ophthalmol J. 2009;3(2):38\u201342. https:\/\/doi.org\/10.2174\/1874364100903020038.","journal-title":"Open Ophthalmol J"},{"issue":"1","key":"6862_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41433-019-0633-6","volume":"34","author":"A Garg","year":"2020","unstructured":"Garg A, Gazzard G. Treatment choices for newly diagnosed primary open angle and ocular hypertension patients. Eye. 2020;34(1):60\u201371. https:\/\/doi.org\/10.1038\/s41433-019-0633-6.","journal-title":"Eye"},{"issue":"10","key":"6862_CR8","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/bjo.86.10.1080","volume":"86","author":"JTF Lau","year":"2002","unstructured":"Lau JTF, Lee V, Fan D, Lau M, Michon J. Knowledge about cataract, glaucoma, and age related macular degeneration in the Hong Kong Chinese population. Br J Ophthalmol. 2002;86(10):1080\u20134. https:\/\/doi.org\/10.1136\/bjo.86.10.1080.","journal-title":"Br J Ophthalmol"},{"key":"6862_CR9","first-page":"1902","volume":"6420","author":"DS Friedman","year":"2002","unstructured":"Friedman DS, Jampel HD, Lubomski LH, Kempen JH, Quigley H, Congdon N, et al. Surgical strategies for coexisting Glaucoma and cataract - an evidence-based update. Am Acad Ophthalmol. 2002;6420:1902\u201313.","journal-title":"Am Acad Ophthalmol"},{"issue":"8","key":"6862_CR10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/IJG.0000000000000720","volume":"26","author":"K Vinod","year":"2017","unstructured":"Vinod K, Gedde SJ, Feuer WJ, Panarelli JF, Chang TC, Chen PP, et al. Practice preferences for Glaucoma surgery: a survey of the American Glaucoma Society. J Glaucoma. 2017;26(8):687\u201393. https:\/\/doi.org\/10.1097\/IJG.0000000000000720 Lippincott Williams and Wilkins.","journal-title":"J Glaucoma"},{"issue":"11","key":"6862_CR11","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.jcrs.2009.05.061","volume":"35","author":"BJ Poley","year":"2009","unstructured":"Poley BJ, Lindstrom RL, Samuelson TW, Schulze R. Intraocular pressure reduction after phacoemulsification with intraocular lens implantation in glaucomatous and nonglaucomatous eyes evaluation of a causal relationship between the natural lens and open-angle glaucoma. J Cart Refract Surg. 2009;35(11):1946\u201355. https:\/\/doi.org\/10.1016\/j.jcrs.2009.05.061.","journal-title":"J Cart Refract Surg"},{"issue":"2","key":"6862_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/ICU.0b013e3283360ac3","volume":"21","author":"A Shrivastava","year":"2010","unstructured":"Shrivastava A, Singh K. The effect of cataract extraction on intraocular pressure. Curr Opin Ophthalmol. 2010;21(2):118\u201322. https:\/\/doi.org\/10.1097\/ICU.0b013e3283360ac3.","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"6862_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/IIO.0000000000000234","volume":"58","author":"JD Ling","year":"2018","unstructured":"Ling JD, Bell NP. Role of cataract surgery in the Management of Glaucoma. Int Ophthalmol Clin. 2018;58(3):87\u2013100. https:\/\/doi.org\/10.1097\/IIO.0000000000000234.","journal-title":"Int Ophthalmol Clin"},{"key":"6862_CR14","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.ophtha.2012.02.050","volume":"119","author":"S Mansberger","year":"2012","unstructured":"Mansberger S, Gordon M, Jampel H, Bhorade A, Brandt JD, Wilson B, et al. Reduction in intraocular pressure after cataract extraction: the Ocular Hypertension Treatment Study. Ophthalmology. 2012;119:1826\u2013183. https:\/\/doi.org\/10.1016\/j.ophtha.2012.02.050.","journal-title":"Ophthalmology"},{"key":"6862_CR15","volume-title":"Terminology and Guidelines for Glaucoma","author":"European Glaucoma Society","year":"2017","unstructured":"European Glaucoma Society. Chapter 3: Treatment principles and options. In: Terminology and Guidelines for Glaucoma. 4th ed; 2017.","edition":"4"},{"issue":"6","key":"6862_CR16","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.ophtha.2019.03.006","volume":"126","author":"TW Samuelson","year":"2019","unstructured":"Samuelson TW, Sarkisian SR, Lubeck DM, Stiles MC, Duh YJ, Romo EA, et al. Prospective, randomized, controlled pivotal trial of an ab Interno implanted trabecular Micro-bypass in primary open-angle Glaucoma and cataract: two-year results. Ophthalmology. 2019;126(6):811\u201321. https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.006.","journal-title":"Ophthalmology"},{"key":"6862_CR17","volume-title":"Long-Term IOP and Medication reduction with second-generation MIGS trabecular micro-bypass stents for OAG patients on one preoperative medication","author":"K Schargel","year":"2018","unstructured":"Schargel K, Belda J, Rial L. Long-Term IOP and Medication reduction with second-generation MIGS trabecular micro-bypass stents for OAG patients on one preoperative medication. Florence: Poster presented at: EGS 2018, 13th EGS Congress; 2018."},{"key":"6862_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/1056573","volume":"2016","author":"P Arriola-Villalobos","year":"2016","unstructured":"Arriola-Villalobos P, Martinez-De-La-Casa JM, Diaz-Valle D, Morales-Fernandez L, Fernandez-Perez C, Garcia-Feijoo J. Glaukos iStent inject\u00ae trabecular Micro-bypass implantation associated with cataract surgery in patients with coexisting cataract and open-angle Glaucoma or ocular hypertension: a long-term study. J Ophthalmol. 2016;2016:1\u20137. https:\/\/doi.org\/10.1155\/2016\/1056573.","journal-title":"J Ophthalmol"},{"key":"6862_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2147\/OPTH.S59932","volume":"8","author":"AM Fea","year":"2014","unstructured":"Fea AM, Belda JI, Rekas M, J\u00fcnemann A, Chang L, Pablo L, et al. Prospective unmasked randomized evaluation of the iStent inject\u00ae versus two ocular hypotensive agents in patients with primary open-angle glaucoma. Clin Ophthalmol. 2014;8:875\u201382. https:\/\/doi.org\/10.2147\/OPTH.S59932.","journal-title":"Clin Ophthalmol"},{"key":"6862_CR20","unstructured":"Poitras DV, Wells C, Hutnik DC, Klarenback DS, So H, Tsoi DB, et al. Economic Evaluation: Canadian Agency for Drugs and Technologies in Health; 2019. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK543897\/"},{"issue":"1","key":"6862_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40123-018-0131-0","volume":"7","author":"P Agrawal","year":"2018","unstructured":"Agrawal P, Bradshaw SE. Systematic literature review of clinical and economic outcomes of Micro-Invasive Glaucoma Surgery (MIGS) in Primary Open-Angle Glaucoma. Ophthalmol Ther. 2018;7(1):49\u201373. https:\/\/doi.org\/10.1007\/s40123-018-0131-0 Springer Healthcare.","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"6862_CR22","doi-asserted-by":"publisher","first-page":"e0252130","DOI":"10.1371\/journal.pone.0252130","volume":"16","author":"K Nieland","year":"2021","unstructured":"Nieland K, Labb\u00e9 A, Schweitzer C, Gicquel G, Kleintjens J, Ostawal A, et al. A cost-effectiveness analysis of iStent inject combined with phacoemulsification cataract surgery in patients with mild-to-moderate open-angle glaucoma in France. PLoS One. 2021;16(6):e0252130. https:\/\/doi.org\/10.1371\/journal.pone.0252130.","journal-title":"PLoS One"},{"issue":"4","key":"6862_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/13696998.2019.1572013","volume":"22","author":"V Patel","year":"2019","unstructured":"Patel V, Ahmed I, Podbielski D, Falvey H, Murray J, Goeree R. Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada. J Med Econ. 2019;22(4):390\u2013401. https:\/\/doi.org\/10.1080\/13696998.2019.1572013 Taylor and Francis Ltd.","journal-title":"J Med Econ"},{"issue":"1","key":"6862_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1874364100903010059","volume":"3","author":"R Susanna Jr","year":"2009","unstructured":"Susanna R Jr. Staging Glaucoma patient: why and how? Open Ophthalmol J. 2009;3(1):59\u201364. https:\/\/doi.org\/10.2174\/1874364100903010059.","journal-title":"Open Ophthalmol J"},{"issue":"10","key":"6862_CR25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/bjo.2005.067355","volume":"89","author":"CE Traverso","year":"2005","unstructured":"Traverso CE, Walt JG, Kelly SP, Hommer AH, Bron AM, Denis P, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol. 2005;89(10):1245\u20139. https:\/\/doi.org\/10.1136\/bjo.2005.067355.","journal-title":"Br J Ophthalmol"},{"key":"6862_CR26","unstructured":"Glaukos. Expert opinion 2019. Data on file."},{"key":"6862_CR27","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","volume":"112","author":"CM Olthoff","year":"2005","unstructured":"Olthoff CM, Schouten JS, Van De Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension: An evidence-based review. Ophthalmology. 2005;112:953\u2013961.e7. https:\/\/doi.org\/10.1016\/j.ophtha.2004.12.035 Elsevier Inc.","journal-title":"Ophthalmology"},{"issue":"4","key":"6862_CR28","doi-asserted-by":"publisher","first-page":"598.e1","DOI":"10.1016\/j.ajo.2005.04.051","volume":"140","author":"BL Nordstrom","year":"2005","unstructured":"Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598.e1\u2013598.e11. https:\/\/doi.org\/10.1016\/j.ajo.2005.04.051.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"6862_CR29","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ophtha.2010.07.007","volume":"118","author":"TW Samuelson","year":"2011","unstructured":"Samuelson TW, Katz LJ, Wells JM, Duh YJ, Giamporcaro JE. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118(3):459\u201367. https:\/\/doi.org\/10.1016\/j.ophtha.2010.07.007.","journal-title":"Ophthalmology"},{"issue":"10","key":"6862_CR30","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the early manifest Glaucoma trial. Arch Ophthalmol. 2002;120(10):1268\u201379. https:\/\/doi.org\/10.1001\/archopht.120.10.1268.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"6862_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48\u201356. https:\/\/doi.org\/10.1001\/archopht.121.1.48.","journal-title":"Arch Ophthalmol"},{"key":"6862_CR32","unstructured":"National Collaborating Centre for Acute Care. Glaucoma. In: Diagnosis and managenement of chronic open angle glaucoma and ocular hypertension: NICE; 2009. Available: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21938863."},{"key":"6862_CR33","volume-title":"Resident Population","author":"National Statistics Institute (ISTAT)","year":"2017","unstructured":"National Statistics Institute (ISTAT). Resident Population 2017. Available: http:\/\/demo.istat.it\/tvm2016\/index.php?lingua=ita."},{"key":"6862_CR34","unstructured":"Region Umbria. Outpatient intervention tariffs. DGR 1698. 29\/12\/2011. Accessed 1 July 2021."},{"key":"6862_CR35","unstructured":"Region Veneto. Outpatient intervention tariffs. DGR 859. 21\/06\/2011. Accessed 1 July 2021."},{"key":"6862_CR36","unstructured":"Region Tuscany. Outpatient intervention tariffs. DGR 723. 04\/08\/2011. Accessed 1 July 2021."},{"key":"6862_CR37","unstructured":"Glaukos. Market data 2019. Data on file."},{"key":"6862_CR38","unstructured":"Italian Ministry of Health. Inpatient intervention tariffs: Italian Republic Official Gazette; 2013a."},{"key":"6862_CR39","unstructured":"Region Friuli Venezia-Giulia. Outpatient intervention tariffs. DGR 1971. 21\/10\/2016. Accessed 1 July 2021."},{"key":"6862_CR40","unstructured":"Region Molise. Outpatient intervention tariffs. DGR 31. 21\/03\/2013. Accessed 1 July 2021"},{"key":"6862_CR41","unstructured":"Italian Medicines Agency (AIFA). List of equivalent drugs. 15\/10\/2019. Available: https:\/\/www.aifa.gov.it\/documents\/20142\/825643\/Lista_farmaci_equivalenti_Principio_Attivo_15.10.2019.pdf\/68d24bfe-ff49-4aa2-d53c-6efbe7a02b76. Accessed 1 July 2021."},{"key":"6862_CR42","unstructured":"Italian Medicines Agency (AIFA). List of Class A drugs. 17\/06\/2019. Available: https:\/\/www.aifa.gov.it\/liste-farmaci-a-h. Accessed 1 July 2021."},{"key":"6862_CR43","volume-title":"L\u2019uso dei farmaci in Italia","author":"Osservatorio Nazionale sull\u2019Impiego dei Medicinali (OSMED)","year":"2018","unstructured":"Osservatorio Nazionale sull\u2019Impiego dei Medicinali (OSMED). L\u2019uso dei farmaci in Italia. 2018. Available: https:\/\/www.aifa.gov.it\/web\/guest\/-\/rapporto-osmed-20-1."},{"key":"6862_CR44","unstructured":"Italian Ministry of Health. Outpatient intervention tariffs: Italian Republic Official Gazette; 2013a."},{"key":"6862_CR45","volume-title":"Trabecular Micro-Bypass System (Data on file)","author":"Report Glaukos iStent Inject\u00ae","year":"2019","unstructured":"Report Glaukos iStent Inject\u00ae. Trabecular Micro-Bypass System (Data on file). 2019."},{"issue":"1","key":"6862_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1755-3768.2011.02318.x","volume":"90","author":"A Van Gestel","year":"2012","unstructured":"Van Gestel A, Webers CA, Severens JL, Beckers HJ, Jansonius NM, Hendrikse F, et al. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. Acta Ophthalmol. 2012;90(1):20\u201331. https:\/\/doi.org\/10.1111\/j.1755-3768.2011.02318.x.","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"6862_CR47","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/eye.2010.133","volume":"24","author":"A Van Gestel","year":"2010","unstructured":"Van Gestel A, Webers CAB, Beckers HJM, Van Dongen MCJM, Severens JL, Hendrikse F, et al. The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye. 2010;24(12):1759\u201369. https:\/\/doi.org\/10.1038\/eye.2010.133 Nature Publishing Group.","journal-title":"Eye"},{"issue":"6","key":"6862_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/aos.12328","volume":"92","author":"A Van Gestel","year":"2014","unstructured":"Van Gestel A, Schouten JSAG, Beckers HJM, Severens JL, Hendrikse F, Webers CAB. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension. Acta Ophthalmol. 2014;92(6):513\u201323. https:\/\/doi.org\/10.1111\/aos.12328.","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"6862_CR49","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ajo.2011.06.004","volume":"152","author":"R Varma","year":"2011","unstructured":"Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 2011;152(4):515\u201322. https:\/\/doi.org\/10.1016\/j.ajo.2011.06.004.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"6862_CR50","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1159\/000104765","volume":"221","author":"D Koleva","year":"2007","unstructured":"Koleva D, Motterlini N, Schiavone M, Garattini L. Medical costs of glaucoma and ocular hypertension in Italian referral centres: a prospective study. Ophthalmologica. 2007;221(5):340\u20137. https:\/\/doi.org\/10.1159\/000104765.","journal-title":"Ophthalmologica"},{"issue":"3","key":"6862_CR51","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jcrs.2009.10.031","volume":"36","author":"AM Fea","year":"2010","unstructured":"Fea AM. Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma. Randomized double-masked clinical trial. J Cataract Refract Surg. 2010;36(3):407\u201312. https:\/\/doi.org\/10.1016\/j.jcrs.2009.10.031 ASCRS and ESCRS.","journal-title":"J Cataract Refract Surg"},{"key":"6862_CR52","first-page":"83","volume":"11","author":"G Fattore","year":"2009","unstructured":"Fattore G. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. PharmacoEconomics. 2009;11:83\u201393.","journal-title":"PharmacoEconomics"},{"issue":"2","key":"6862_CR53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/ceo.12805","volume":"45","author":"AM Fea","year":"2017","unstructured":"Fea AM, Ahmed IIK, Lavia C, Mittica P, Consolandi G, Motolese I, et al. Hydrus microstent compared to selective laser trabeculoplasty in primary open angle glaucoma: one year results. Clin Exp Ophthalmol. 2017;45(2):120\u20137. https:\/\/doi.org\/10.1111\/ceo.12805 Blackwell Publishing.","journal-title":"Clin Exp Ophthalmol"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-06862-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-021-06862-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-021-06862-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T20:22:46Z","timestamp":1629145366000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-021-06862-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6862"],"URL":"https:\/\/doi.org\/10.1186\/s12913-021-06862-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-267336\/v1","asserted-by":"object"}]},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"22 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Furneri G.: consulting fees from Glaukos for analysis conduction.Fea A.M.: consulting fees from Glaukos, Ivantis, ELTSight, iSTAR, and EyeD; travel fees from Johnson and Johnson, Allergan, and Sooft, outside the submitted work.Buseghin G.: employee of Glaukos.No further CoI were declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"824"}}